Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
poly iclc
- Development stage
- Phase 2
- Lead developer
- Oncovir
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Systemic Administration
01
Overview
Poly ICLC is a synthetic immunostimulant composed of polyinosinic-polycytidylic acid (poly I:C) complexed with the stabilizers carboxymethylcellulose and poly-L-lysine. It acts as a viral double-stranded RNA mimic, recognized by pattern recognition receptors such as toll-like receptor 3 (TLR3), MDA5, and DDX/DHX RNA helicases. By activating these innate immune sensors, Poly ICLC induces the production of type I interferons and pro-inflammatory cytokines, enhances dendritic cell activation, promotes Th1 polarization, and stimulates cytotoxic T cell responses. Its primary clinical development has been as an adjuvant in cancer immunotherapy—both as a direct antitumor agent and to enhance vaccine efficacy—and it is also being investigated for other indications involving immune modulation[1][2][3][4][5][6].
- Brand names
- hiltonol
- Other names
- polyinosinic-polycytidylic acid stabilized with poly-l-lysine and carboxymethylcellulosepiclc
02
Targets
IFIH1 (MDA5)TLR3 (Toll-like receptor 3)
Beyond the preview
Go deeper on poly iclc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on poly iclc.